![]() | Maxwell Enterprises
Mominpura, Nagpur, Maharashtra |
Approx. 1,000 / Piece Get Latest Price
While exact formulations vary, Photon Gard Lotion generally includes:
Titanium Dioxide / Zinc Oxide: Acts as a physical barrier to UV radiation and post-radiation sensitivity
Allantoin: Promotes wound healing, soothes irritated skin
Aloe Vera Extract: Anti-inflammatory and cooling effect
Vitamin E Acetate: Antioxidant that supports skin repair
Panthenol (Pro-vitamin B5): Enhances skin hydration and regeneration
Silicone-based emollients: Protect skin integrity and reduce friction
Optional: Soothing agents (e.g., calendula, chamomile) and anti-microbial preservatives
Used in patients undergoing radiation therapy for cancer to:
Prevent or manage radiation dermatitis
Relieve erythema, burning, dryness, and peeling
Enhance skin barrier recovery during or post-radiotherapy
Forms a physical and chemical barrier on irradiated skin
Helps soothe inflammation, reduce oxidative stress, and repair epithelial damage
Apply a thin, even layer over the irradiated area
Typically used 2–3 times daily, especially:
After radiation sessions
Before bedtime
Should not be applied immediately before radiation (wait at least 2 hours if needed)
External use only
Do not apply on broken skin or open wounds unless advised
Avoid use immediately before radiation therapy
Store at room temperature, away from heat and direct sunlight
Photon Gard is part of the supportive care toolkit in radiation oncology
Prescribed in conjunction with radiation shielding techniques
Alternative products include: Aloe-based gels, Biafine cream, Calendula lotion, RadiaCare gel, etc.
Approx. 800 / Box Get Latest Price
Minimum Order Quantity | 10 Box |
Strength | 25 mg |
Generic Name | Sunitinib Malate |
Item Name | Sunixar 25 mg |
Packing | 1 blister |
Country of Origin | Made in India |
Active Ingredient: Nintedanib
Dosage Forms: Oral capsules/tablets
Strengths: 12.5 mg (Nitnib), 25 mg (Sunixar), 50 mg (Sutykine)
Tyrosine kinase inhibitor (TKI)
Targets VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), FGFR (fibroblast growth factor receptor)
Nintedanib inhibits multiple receptor tyrosine kinases involved in angiogenesis and fibrosis pathways.
By blocking these signals, it reduces tumor growth and progression in cancers and slows fibrosis in lung diseases.
Idiopathic Pulmonary Fibrosis (IPF) — slows progression of lung fibrosis
Non-Small Cell Lung Cancer (NSCLC) — used in combination with chemotherapy for certain adenocarcinomas
Other fibrotic lung diseases (sometimes off-label)
Strength | Typical Use Case | Dose Considerations |
---|---|---|
12.5 mg (Nitnib) | Initiation/titration in sensitive patients | Used to start therapy or reduce side effects |
25 mg (Sunixar) | Standard maintenance dosing | Often prescribed as part of maintenance or mid-dose treatment |
50 mg (Sutykine) | Full therapeutic dosing for advanced cases | Used in higher dose regimens, especially in cancer therapy |
Usually taken twice daily with food to reduce gastrointestinal side effects
Dose adjustments may be necessary based on tolerance and liver function
Common: Diarrhea, nausea, vomiting, abdominal pain, liver enzyme elevation
Serious: Hepatotoxicity, bleeding risk, gastrointestinal perforation (rare)
Regular liver function tests recommended during therapy
Store at room temperature (20–25°C)
Protect from moisture and light
Monitor liver function tests regularly
Caution in patients with hepatic impairment
Avoid during pregnancy and breastfeeding
Use with caution in patients with bleeding risk or recent surgery